Bausch Health Companies Inc. (BVF)
Summary
BVF Chart
Can Bausch (BHC) Run Higher on Rising Earnings Estimates?
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine
Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based revenue growth (9% YoY), significant margin expansion, and strong operating cash flow, supporting an optimistic outlook. Premium intraocular lenses and branded pharmaceuticals are driving faster growth, improving mix, and enabling margin and EBITDA expansion without unsustainable revenue acceleration.
Bausch Health Companies Inc. (BVF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bausch Health Companies Inc. ever had a stock split?
Bausch Health Companies Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Thomas J. Appio CEO | XFRA Exchange | CA0717341071 ISIN |
| CA Country | 20,300 Employees | 11 Jun 2014 Last Dividend | 16 Oct 2000 Last Split | - IPO Date |
Overview
Bausch Health Companies Inc. is a global player in the specialized pharmaceutical and medical device sector, with operations spanning both the United States and numerous other countries around the world. Its focus areas include gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. Originally known as Valeant Pharmaceuticals International, Inc., the company underwent a name change in July 2018, marking a new chapter in its history. Headquartered in Laval, Canada, the organization functions through five key segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb, each targeting specific market needs.
Products and Services
Bausch Health's diverse portfolio extends across various medical domains, including:
- Gastroenterology: Under the Salix segment, the company provides innovative products aimed at gastrointestinal health, catering primarily to the US market.
- International Pharmaceutical and Medical Devices: The International segment encompasses the distribution of branded and generic pharmaceuticals, OTC products, and aesthetic medical devices across different countries, focusing on meeting global health needs.
- Aesthetic Medical Devices: Through the Solta Medical segment, Bausch Health engages in the development and sale of cutting-edge aesthetic devices, showcasing its commitment to advancing beauty and dermatological care.
- Diversified Products: The Diversified segment offers a wide range of pharmaceuticals in neurology and various other therapeutic classes, including generic products, ortho dermatologic products, and dentistry products within the US. This diversification underscores the company's holistic approach to healthcare.
- Vision Care and Ophthalmic Products: The Bausch + Lomb segment, named after the well-known eye health brand, provides a comprehensive line of products to address vision care, surgical requirements, and ophthalmic pharmaceutical needs, underlining Bausch Health's prominence in eye health solutions.
